The story of Eli Lilly, a Civil War veteran with a chemist’s instinct and an entrepreneur’s stubbornness who opened a small pharmacy in Indianapolis in 1876 with the sign above the door simply reading “Eli Lilly, Chemist,” has a subtly cinematic quality.
That same company reached a milestone that no healthcare company had ever reached nearly a century and a half later. Eli Lilly became the first healthcare company in history to reach a market capitalization of $1 trillion in November 2025. This is the kind of milestone that causes investors to halt in their tracks.
| Category | Details |
|---|---|
| Full Name | Eli Lilly and Company |
| Founded | 1876, by Colonel Eli Lilly |
| Headquarters | Indianapolis, Indiana, USA |
| Ticker Symbol | NYSE: LLY |
| Global Offices | 18 countries |
| Products Sold In | Approximately 125 countries |
| Fortune 500 Rank | 100th |
| Forbes Global 2000 Rank | 138th |
| Market Capitalization | Reached $1 trillion in November 2025 |
| Top Product (2024) | Tirzepatide — Mounjaro & Zepbound (37% of revenue) |
| U.S. Revenue Share (2024) | 67% |
| Biomedical Rank by Revenue | 4th largest globally |
| Notable First | First health-care company in the world to reach $1 trillion market cap |
| Charitable Arm | Lilly Endowment (owns 10% of company, founded 1937) |
Tirzepatide, marketed as Mounjaro for type 2 diabetes and Zepbound for weight loss and obstructive sleep apnea, is the driving force behind that rise. This one compound was responsible for 37% of the company’s total sales in 2024 alone.
That’s an incredible concentration of financial power in one molecule, which begs the obvious question of what would happen if rivals closed the gap or if pricing pressure eventually materialized. The precise moment and manner in which those pressures could bite are still unknown. However, the numbers are currently going in a single direction.
It’s simple to overlook how Lilly got here in the first place amid all the financial clamor. Wall Street wasn’t always fond of the company. It was the first to manufacture the polio vaccine in large quantities and the first to create human insulin using recombinant DNA, making it a reputable pharmaceutical brand for many years. It became well-known in the late 1980s thanks to Prozac.
Zyprexa came next. However, those medications are no longer under patent and are produced as generic versions by other companies. GLP-1 receptor agonists, a class of medications that Lilly itself helped pioneer when it introduced exenatide to the market back in 2005, provided Lilly with a fresh narrative to tell.
Watching this unfold gives me the impression that the company made an incredible long-term wager that most people didn’t fully recognize until Mounjaro began changing the national dialogue about weight loss. The market for obesity medications is huge and may represent the biggest therapeutic opportunity in pharmaceutical history. Lilly didn’t fall into it by accident. It worked toward it for years. It’s difficult to say with certainty whether that foresight was the result of strategic brilliance or lucky timing—probably a combination of the two.
The partnership with Amazon Pharmacy, which is now providing Foundayo, Lilly’s recently approved once-daily oral GLP-1 treatment, for adults with obesity or weight-related medical conditions, is the most recent development worth keeping an eye on. With prices as low as $1 per day with insurance and $5 per day for cash-paying clients, same-day delivery is available in almost 3,000 cities.
The industry has never really seen a pharmaceutical product with that level of retail power, and investors seem to think it matters. When it comes to weight loss, Lilly and Amazon together make a significant statement.
In the meantime, financial disclosures continue to be made in Washington. In March 2026, California Representative Gilbert Ray Cisneros Jr. reportedly sold Eli Lilly stock for between $1,001 and $15,000. In the grand scheme of things, it’s a small transaction, but congressional stock sales involving a company this well-known tend to attract attention and raise the kinds of questions that don’t always have clear answers.
12% of 2024 sales came from abemaciclib, which is marketed as Verzenio for advanced breast cancer. Another 12% was added by dulaglutide, also referred to as Trulicity. These medications are not insignificant; they are the culmination of years of research, successful clinical trials, and transformed lives. However, the reality is that tirzepatide comes up in practically every analyst discussion these days. It’s difficult to ignore how drastically one product can change a company this size’s center of gravity.
Lilly, which is ranked 100th on the Fortune 500 and fourth globally in terms of revenue among biomedical companies, is now the story rather than the underdog. Approximately 10% of the company is still owned by the Lilly Endowment, a charitable foundation established by the founding family in 1937. That continuity has a grounding quality.
A company that started out selling quinine for treating malaria with three employees and $4,470 in sales by the end of its first year is now measuring its impact in the global healthcare system in trillions. The original chemist probably wouldn’t know what to think of it. However, investors appear to have a strong opinion.
